Lanean...

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

This phase 1/2 trial evaluated the maximum tolerated doses, safety, and efficacy of pomalidomide, bortezomib, and dexamethasone (PVD) combination in patients with relapsed lenalidomide-refractory multiple myeloma (MM). In phase 1, dose level 1 consisted of pomalidomide (4 mg by mouth on days 1 to 21...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Paludo, Jonas, Mikhael, Joseph R., LaPlant, Betsy R., Halvorson, Alese E., Kumar, Shaji, Gertz, Morie A., Hayman, Suzanne R., Buadi, Francis K., Dispenzieri, Angela, Lust, John A., Kapoor, Prashant, Leung, Nelson, Russell, Stephen J., Dingli, David, Go, Ronald S., Lin, Yi, Gonsalves, Wilson I., Fonseca, Rafael, Bergsagel, P. Leif, Roy, Vivek, Sher, Taimur, Chanan-Khan, Asher A., Ailawadhi, Sikander, Stewart, A. Keith, Reeder, Craig B., Richardson, Paul G., Rajkumar, S. Vincent, Lacy, Martha Q.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2017
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5606008/
https://ncbi.nlm.nih.gov/pubmed/28684537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-782961
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!